NEW YORK – Igenomix and Ferring Pharmaceuticals said on Thursday that they have entered into a two-year research collaboration to discover novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia.
The companies said they are aiming to develop diagnostics and therapeutics in these areas of high unmet need. Under the terms of the deal, Igenomix, based in Valencia, Spain, and Ferring, headquartered in Saint-Prex, Switzerland, will create a new research hub in Boston to help their respective scientists work together. The hub will focus on investigating molecular signatures, developing novel functional genomic systems, and creating translational tools to study embryo implantation, endometrial microbiome interactions, and decidualization biology.
Financial terms of the deal were not disclosed.
"This new research hub will connect Igenomix's unique diagnostic capabilities with Ferring's deep therapeutic expertise," Carlos Simón, head of Igenomix Foundation's scientific board and project lead for the new hub, said in a statement. "We believe this collaboration will accelerate scientific findings and improve conception rates at a time when significant progress is needed in preimplantation science to help more women and families experience healthy pregnancies."